Element contents
Series: Elements in Public Economics
Public Health Care
Published online by Cambridge University Press: 10 March 2025
Summary
This Element discusses the role of the government in the financing and provision of public health care. It summarises core knowledge and findings in the economics literature, giving a state-of-the-art account of public health care. The first section is devoted to health system financing. It provides policy rationales for public health insurance which rely on both equity and efficiency, the co-existence of public and private health insurance, how health systems deal with excess demand, and the effect of health insurance expansion. The second section covers the provision of health care and the effect of policy interventions that aim at improving quality and efficiency, including reimbursement mechanisms, competition, public–private mix, and integrated care. The third section is devoted to the market for pharmaceuticals, focusing on the challenges of regulating on-patent and off-patent markets, and discussing the main incentives for pharmaceutical innovation.
- Type
- Element
- Information
- Series: Elements in Public EconomicsOnline ISBN: 9781108652537Publisher: Cambridge University PressPrint publication: 30 April 2025
References
Askildsen, J. E., Holmås, T. H., and Kaarboe, O., 2010. Prioritization and patients’ rights: Analysing the effect of a reform in the Norwegian hospital sector. Social Science & Medicine, 70(2), pp. 199–208.CrossRefGoogle ScholarPubMed
Askildsen, J. E., Holmås, T. H., and Kaarboe, O., 2011. Monitoring prioritisation in the public health‐care sector by use of medical guidelines: The case of Norway. Health Economics, 20(8), pp. 958–970.CrossRefGoogle ScholarPubMed
Auerbach, A. J. and Hines, J. R., 2002. Taxation and economic efficiency. In Auerbach, A. J. and Feldstein, M., eds., Handbook of Public Economics. Amsterdam: Elsevier, pp. 1347–1421.Google Scholar
Avdic, D., Moscelli, G., Pilny, A., and Sriubaite, I., 2019. Subjective and objective quality and choice of hospital: Evidence from maternal care services in Germany. Journal of Health Economics, 68, p. 102229.CrossRefGoogle ScholarPubMed
Baicker, K., Taubman, S. L., Allen, H. L., et al., 2013. The Oregon experiment – effects of medicaid on clinical outcomes. New England Journal of Medicine, 368(18), pp. 1713–1722.CrossRefGoogle ScholarPubMed
Baicker, K., Mullainathan, S., and Schwartzstein, J., 2015. Behavioral hazard in health insurance. The Quarterly Journal of Economics, 130(4), pp. 1623–1667.CrossRefGoogle ScholarPubMed
Barbaresco, S., Courtemanche, C. J., and Qi, Y., 2015. Impacts of the Affordable Care Act dependent coverage provision on health-related outcomes of young adults. Journal of Health Economics, 40, pp. 54–68.CrossRefGoogle ScholarPubMed
Barbetta, G. P., Turati, G., and Zago, A. M., 2007. Behavioral differences between public and private not‐for‐profit hospitals in the Italian national health service. Health Economics, 16(1), pp. 75–96.CrossRefGoogle ScholarPubMed
Bardey, D., Bommier, A., and Jullien, B., 2010. Retail price regulation and innovation: Reference pricing in the pharmaceutical industry. Journal of Health Economics, 29, pp. 303–316.CrossRefGoogle ScholarPubMed
Barros, P. P. and Siciliani, L., 2011. Public and private sector interface. In Handbook of Health Economics (Vol. 2). Amsterdam: Elsevier, pp. 927–1001.Google Scholar
Batty, M. and Ippolito, B., 2017. Financial incentives, hospital care, and health outcomes: Evidence from fair pricing laws. American Economic Journal: Economic Policy, 9(2), pp. 28–56.Google Scholar
Bauhoff, S., 2012. Do health plans risk-select? An audit study on Germany’s Social Health Insurance. Journal of Public Economics, 96(9–10), pp. 750–759.Google Scholar
Bauhoff, S., Hotchkiss, D. R., and Smith, O., 2011. The impact of medical insurance for the poor in Georgia: A regression discontinuity approach. Health Economics, 20(11), pp. 1362–1378.CrossRefGoogle Scholar
Baumgartner, C. and Busato, A., 2012. Risikoselektion in der Grundversicherung. Schweizerische Ärztezeitung, 93, pp. 510–513.Google Scholar
Baxter, S., Johnson, M., Chambers, D., et al., 2018. The effects of integrated care: A systematic review of UK and international evidence. BMC Health Services Research, 18, pp. 1–13.CrossRefGoogle ScholarPubMed
Beckert, W., Christensen, M., and Collyer, K., 2012. Choice of NHS‐Funded hospital services in England. The Economic Journal, 122(560), pp. 400–417.CrossRefGoogle Scholar
Bennato, A. R. and Valletti, T., 2014. Pharmaceutical innovation and parallel trade. International Journal of Industrial Organization, 33, pp. 83–92.CrossRefGoogle Scholar
Bennett, D., Hung, C.-L., and Lauderdale, T.-L., 2015. Health care competition and antibiotic use in Taiwan. Journal of Industrial Economics, 63(2), pp. 371–393.CrossRefGoogle Scholar
Bernal, N., Carpio, M. A., and Klein, T. J., 2017. The effects of access to health insurance: Evidence from a regression discontinuity design in Peru. Journal of Public Economics, 154, pp. 122–136.CrossRefGoogle Scholar
Berta, P., Martini, G., Moscone, F., and Vittadini, G., 2016. The association between asymmetric information, hospital competition and quality of healthcare: Evidence from Italy. Journal of the Royal Statistical Society Series A: Statistics in Society, 179(4), pp. 907–926.CrossRefGoogle Scholar
Beukers, P. D., Kemp, R. G., and Varkevisser, M., 2014. Patient hospital choice for hip replacement: Empirical evidence from the Netherlands. The European Journal of Health Economics, 15, pp. 927–936.CrossRefGoogle ScholarPubMed
Biglaiser, G. and Ma, C. T. A., 2003. Price and quality competition under adverse selection: Market organization and efficiency. RAND Journal of Economics, 34(2), pp. 266–286.CrossRefGoogle Scholar
Birg, L., 2023. Pharmaceutical regulation under market integration through parallel trade. Canadian Journal of Economics, 56, pp. 1322–1346.CrossRefGoogle Scholar
Bloom, N., Propper, C., Seiler, S., and Van Reenen, J., 2015. The impact of competition on management quality: Evidence from public hospitals. The Review of Economic Studies, 82(2), pp. 457–489.CrossRefGoogle Scholar
Blume-Kohout, M. E., 2012. Does targeted, disease-specific public research funding influence pharmaceutical innovation? Journal of Policy Analysis and Management, 31(3), pp. 641–660.CrossRefGoogle ScholarPubMed
Brekke, K. R., Königbauer, I., and Straume, O. R., 2007. Reference pricing of pharmaceuticals. Journal of Health Economics, 26, pp. 613–642.CrossRefGoogle Scholar
Brekke, K. R., Siciliani, L., and Straume, O. R., 2011a. Hospital competition and quality with regulated prices. Scandinavian Journal of Economics, 113(2), pp. 444–469.CrossRefGoogle Scholar
Brekke, K. R., Holmås, T. H., and Straume, O. R., 2011b. Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment. Journal of Public Economics, 95, pp. 624–638.CrossRefGoogle Scholar
Brekke, K. R., Siciliani, L., and Straume, O. R., 2012. Quality competition with profit constraints. Journal of Economic Behavior & Organization, 84(2), pp. 642–659.CrossRefGoogle Scholar
Brekke, K. R., Holmås, T. H., and Straume, O. R., 2013. Margins and market shares: Pharmacy incentives for generic substitution. European Economic Review, 61, pp. 116–131.CrossRefGoogle Scholar
Brekke, K. R., Siciliani, L., and Straume, O. R., 2015a. Hospital competition with soft budgets. The Scandinavian Journal of Economics, 117(3), pp. 1019–1048.CrossRefGoogle Scholar
Brekke, K. R., Holmås, and Straume, O. R., 2015b. Price regulation and parallel imports of pharmaceuticals. Journal of Public Economics, 129, pp. 92–105.CrossRefGoogle Scholar
Brekke, K. R., Canta, C., and Straume, O. R., 2016. Reference pricing with endogenous generic entry. Journal of Health Economics, 50, pp. 312–329.CrossRefGoogle ScholarPubMed
Brekke, K. R. and Straume, O. R., 2017. Competition policy for health care provision in Norway. Health Policy, 121(2), pp. 134–140.CrossRefGoogle ScholarPubMed
Brekke, K. R., Holmås, T. H., Monstad, K., and Straume, O. R., 2018. Socio‐economic status and physicians’ treatment decisions. Health Economics, 27(3), pp. e77–e89.CrossRefGoogle ScholarPubMed
Brekke, K. R., Canta, C., Siciliani, L., and Straume, O. R., 2021. Hospital competition in a national health service: Evidence from a patient choice reform. Journal of Health Economics, 79, p. 102509.CrossRefGoogle Scholar
Brekke, K. R., Dalen, D. M., and Straume, O. R., 2022. Paying for pharmaceuticals: Uniform pricing versus two-part tariffs. Journal of Health Economics, 83, p. 102613.CrossRefGoogle ScholarPubMed
Brekke, K. R., Dalen, D. M., and Straume, O. R., 2023. The price of cost-effectiveness threshold under therapeutic competition in pharmaceutical markets. Journal of Health Economics, 90, p. 102778.CrossRefGoogle Scholar
Brekke, K. R., Siciliani, L., and Straume, O. R., 2024. Competition, quality and integrated health care. Journal of Health Economics, 95, p. 102880.CrossRefGoogle ScholarPubMed
Breyer, F., Bundorf, M. K., and Pauly, M. V., 2011. Health care spending risk, health insurance, and payment to health plans. In Handbook of Health Economics. Elsevier BV, pp. 691–762.Google Scholar
Brook, R. H., Keeler, E. B., and Lohr, K. N. 2006. The Health Insurance Experiment – A Classic RAND Study Speaks to the Current Health Care Reform Debate, RAND. www.rand.org/content/dam/rand/pubs/research_briefs/2006/RAND_RB9174.pdf.Google Scholar
Bruni, M. L., Ugolini, C., and Verzulli, R., 2021. Should I wait or should I go? Travelling versus waiting for better healthcare. Regional Science and Urban Economics, 89, p. 103697.Google Scholar
Cashin, C., Chi, Y. L., Borowitz, M., and Thompson, S., 2014. Paying for Performance in Healthcare: Implications for Health System Performance and Accountability. Berkshire: McGraw-Hill Education.Google Scholar
Chalkley, M. and Malcomson, J. M., 1998a. Contracting for health services with unmonitored quality. The Economic Journal, 108(449), pp. 1093–1110.CrossRefGoogle Scholar
Chalkley, M. and Malcomson, J. M., 1998b. Contracting for health services when patient demand does not reflect quality. Journal of Health Economics, 17(1), pp. 1–19.CrossRefGoogle Scholar
Chang, S., 2012. The effect of Taiwan’s national health insurance on mortality of the elderly: Revisited. Health Economics, 21(11), pp. 1257–1270.CrossRefGoogle ScholarPubMed
Chard, J., Kuczawski, M., Black, N., and Van der Meulen, J., 2011. Outcomes of elective surgery undertaken in independent sector treatment centres and NHS providers in England: Audit of patient outcomes in surgery. British Medical Journal, 343: d6404, https://www.bmj.com/content/343/bmj.d6404.CrossRefGoogle ScholarPubMed
Chen, L., Yip, W., Chang, M. C., et al., 2007. The effects of Taiwan’s National Health Insurance on access and health status of the elderly. Health Economics, 16(3), pp. 223–242.CrossRefGoogle ScholarPubMed
Chernew, M. E., Rosen, A. B., and Fendrick, A. M., 2007. Value-based insurance design. Health Affairs, 26(2), pp. w195–w203.CrossRefGoogle ScholarPubMed
Chou, S. Y., Grossman, M., and Liu, J. T., 2014. The impact of national health insurance on birth outcomes: A natural experiment in Taiwan. Journal of Development Economics, 111, pp. 75–91.CrossRefGoogle Scholar
Clemens, J. and Gottlieb, J. D., 2014. Do physicians’ financial incentives affect medical treatment and patient health? American Economic Review, 104(4), pp. 1320–1349.CrossRefGoogle ScholarPubMed
Cockburn, I. M., Lanjouw, J. O., and Schankerman, M., 2016. Patents and the global diffusion of new drugs. American Economic Review, 106, pp. 136–164.CrossRefGoogle ScholarPubMed
Cooper, Z., Gibbons, S., Jones, S., and McGuire, A., 2011. Does hospital competition save lives? Evidence from the English NHS patient choice reforms. The Economic Journal, 121(554), pp. F228–F260.CrossRefGoogle ScholarPubMed
Cooper, Z., Gibbons, S., and Skellern, M., 2018. Does competition from private surgical centres improve public hospitals’ performance? Evidence from the English National Health Service. Journal of Public Economics, 166, pp. 63–80.CrossRefGoogle Scholar
Costa-Font, J., McGuire, A., and Varol, N., 2014. Price regulation and relative delays in generic drug adoption. Journal of Health Economics, 38, pp. 1–9.CrossRefGoogle ScholarPubMed
Cremer, H. and Pestieau, P., 1996. Redistributive Taxation and Social Insurance. International Tax and Public Finance, 3, pp. 281–295. https://doi.org/10.1007/BF00418945.CrossRefGoogle Scholar
Cutler, D. M. and Zeckhauser, R. J., 2000. The anatomy of health insurance. In Handbook of Health Economics (Vol. 1). Amsterdam: Elsevier, pp. 563–643.Google Scholar
Dafny, L. S., 2005. How do hospitals respond to price changes? American Economic Review, 95(5), pp. 1525–1547.CrossRefGoogle ScholarPubMed
Dai, R. and Watal, J., 2021. Product patents and access to innovative medicines. Social Science & Medicine, 291, p. 114479.CrossRefGoogle ScholarPubMed
Danzon, P. M. and Pauly, M. V., 2002. Health insurance and the growth in pharmaceutical expenditures. Journal of Law and Economics, 45(S2), pp. 587–613.CrossRefGoogle Scholar
Danzon, P. M., Towse, A., and Mestre-Ferrandiz, J., 2015. Value-based differential pricing: Efficient pricing for drugs in a global context. Health Economics, 24(3), pp. 294–301.CrossRefGoogle Scholar
De Meza, D., 1983. Health insurance and the demand for medical care. Journal of Health Economics, 2(1), pp. 47–54.CrossRefGoogle ScholarPubMed
De Pietro, C., Camenzind, P., Sturny, I., et al., 2015. Switzerland: Health system review. Health Systems in Transition, 17(4), pp. 1–288.Google ScholarPubMed
De Preux, L. B., 2011. Anticipatory ex ante moral hazard and the effect of Medicare on prevention. Health Economics, 20(9), pp. 1056–1072.CrossRefGoogle ScholarPubMed
Di Giacomo, M., Piacenza, M., Siciliani, L., and Turati, G., 2022. The effect of co-payments on the take-up of prenatal tests. Journal of Health Economics, 81, p. 102553.CrossRefGoogle ScholarPubMed
Dubois, P. and Sæthre, M., 2020. On the effect of parallel trade on manufacturers’ and retailers’ profits in the pharmaceutical sector. Econometrica, 88, pp. 2503–2545.CrossRefGoogle Scholar
Duso, T., Herr, A., and Suppliet, M., 2014. The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics. Health Economics, 23, pp. 1036–1057.CrossRefGoogle Scholar
Eggleston, K., 2005. Multitasking and mixed systems for provider payment. Journal of Health Economics, 24(1), pp. 211–223.CrossRefGoogle ScholarPubMed
Eggleston, K., Shen, Y. C., Lau, J., Schmid, C. H., and Chan, J., 2008. Hospital ownership and quality of care: What explains the different results in the literature? Health Economics, 17(12), pp. 1345–1362.CrossRefGoogle ScholarPubMed
Ellis, R. P. and McGuire, T. G., 1986. Provider behavior under prospective reimbursement: Cost sharing and supply. Journal of Health Economics, 5(2), pp. 129–151.CrossRefGoogle ScholarPubMed
Ellis, R. P. and McGuire, T. G., 1990. Optimal payment systems for health services. Journal of Health Economics, 9(4), pp. 375–396.CrossRefGoogle ScholarPubMed
Epple, D. and Romano, R. E., 1996. Ends against the middle: Determining public service provision when there are private alternatives. Journal of Public Economics, 62(3), pp. 297–325.CrossRefGoogle Scholar
Evans, R. G., 2002. Financing healthcare: Taxation and the alternatives. In Mossialos, E. A., Dixon, A., Figueras, J., and Kutzin, J., eds., Funding Health Care: Options for Europe. Buckingham: Open University, pp. 31–58.Google Scholar
Farrar, S., Yi, D., Sutton, M. et al., 2009. Has payment by results affected the way that English hospitals provide care? Difference-in-differences analysis. British Medical Journal, 339, pp. 1–8.CrossRefGoogle ScholarPubMed
Feldman, R. and Dowd, B., 1991. A new estimate of the welfare loss of excess health insurance. American Economic Review, 81(1), pp. 297–301.Google ScholarPubMed
Finkelstein, A., Taubman, S., Wright, B., et al., 2012. The Oregon health insurance experiment: Evidence from the first year. The Quarterly Journal of Economics, 127(3), pp. 1057–1106.CrossRefGoogle Scholar
Foo, P. K., Lee, R. S., and Fong, K., 2017. Physician prices, hospital prices, and treatment choice in labor and delivery. American Journal of Health Economics, 3(3), pp. 422–453.CrossRefGoogle Scholar
Frank, R. G. and Salkever, D. S., 1992. Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal, 59, pp. 165–179.CrossRefGoogle Scholar
Frank, R. G. and Salkever, D. S., 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics & Management Strategy, 6, pp. 75–90.Google Scholar
Gaessler, F. and Wagner, S., 2022. Patents, data exclusivity, and the development of new drugs. Review of Economics & Statistics, 104, pp. 571–586.CrossRefGoogle Scholar
Galizzi, M. M., Ghislandi, S., and Miraldo, M., 2011. Effects of reference pricing in pharmaceutical markets: A review. Pharmacoeconomics, 29, pp. 17–33.CrossRefGoogle ScholarPubMed
Ganslandt, M. and Maskus, K. E., 2004. Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union. Journal of Health Economics, 23, pp. 1035–1057.CrossRefGoogle ScholarPubMed
Garcia Mariñoso, B., Jelovac, I., and Olivella, P., 2011. External referencing and pharmaceutical price negotiation. Health Economics, 20, pp. 737–756.CrossRefGoogle ScholarPubMed
Gaughan, J., Gravelle, H., and Siciliani, L., 2015. Testing the bed‐blocking hypothesis: Does nursing and care home supply reduce delayed hospital discharges? Health Economics, 24, pp. 32–44.CrossRefGoogle ScholarPubMed
Gaughan, J., Gutacker, N., Grašič, K., et al., 2019. Paying for efficiency: Incentivising same-day discharges in the English NHS. Journal of Health Economics, 68, p. 102226.CrossRefGoogle ScholarPubMed
Gaynor, M., 2007. Competition and quality in health care markets. Foundations and Trends® in Microeconomics, 2(6), pp. 441–508.CrossRefGoogle Scholar
Gaynor, M. and Town, R. J., 2011. Competition in health care markets. Handbook of Health Economics, 2, pp. 499–637.CrossRefGoogle Scholar
Gaynor, M., Moreno-Serra, R., and Propper, C., 2013. Death by market power: Reform, competition, and patient outcomes in the National Health Service. American Economic Journal: Economic Policy, 5(4), pp. 134–166.Google Scholar
Gaynor, M., Propper, C., and Seiler, S., 2016. Free to choose? Reform, choice, and consideration sets in the English National Health Service. American Economic Review, 106(11), pp. 3521–3557.CrossRefGoogle ScholarPubMed
Ge, G., Iversen, T., Kaarbøe, O., and Snilsberg, Ø., 2024. Impacts of Norway’s extended free choice reform on waiting times and hospital visits. Health Economics, 33(4), pp. 779–803.CrossRefGoogle ScholarPubMed
Geng, D. and Saggi, K., 2017. International effects of national regulations: External reference pricing and price controls. Journal of International Economics, 109, pp. 68–84.CrossRefGoogle Scholar
Geoffard, P.-Y. and Philipson, T., 1997. Disease eradication: Private versus public vaccination. American Economic Review, 87(1), pp. 222–230.Google Scholar
Ghislandi, S., 2011. Competition and the reference pricing scheme for pharmaceuticals. Journal of Health Economics, 30, pp. 1137–1149.CrossRefGoogle ScholarPubMed
Glaeser, E. L. and Shleifer, A., 2001. Not-for-profit entrepreneurs. Journal of Public Economics, 81(1), pp. 99–115.CrossRefGoogle Scholar
Godøy, A., Haaland, V. F., Huitfeldt, I., and Votruba, M., 2024. Hospital queues, patient health, and labor supply. American Economic Journal: Economic Policy, 16(2), pp. 150–181.Google Scholar
Gonçalves, R. and Rodrigues, V., 2018. Reference pricing with elastic demand for pharmaceuticals. Scandinavian Journal of Economics, 120, pp. 159–182.CrossRefGoogle Scholar
González, P., Macho-Stadler, I., and Pérez-Castrillo, D., 2016. Private versus social incentives for pharmaceutical innovation. Journal of Health Economics, 50, pp. 286–297.CrossRefGoogle ScholarPubMed
Gowrisankaran, G. and Town, R. J., 2003. Competition, payers, and hospital quality 1. Health Services Research, 38(6p1), pp. 1403–1422.CrossRefGoogle Scholar
Grabowski, H. G. and Vernon, J. M., 1992. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics, 35, pp. 331–350.CrossRefGoogle Scholar
Granlund, D. and Bergman, M. A., 2018. Price competition in pharmaceuticals – Evidence from 1303 Swedish markets. Journal of Health Economics, 61, pp. 1–12.CrossRefGoogle ScholarPubMed
Gravelle, H., Smith, P., and Xavier, A., 2003. Performance signals in the public sector: The case of health care. Oxford Economic Papers, 55(1), pp. 81–103.CrossRefGoogle Scholar
Gravelle, H. and Siciliani, L., 2008. Is waiting‐time prioritisation welfare improving? Health Economics, 17(2), pp. 167–184.CrossRefGoogle ScholarPubMed
Gravelle, H., Sutton, M., and Ma, A., 2010. Doctor behaviour under a pay for performance contract: Treating, cheating and case finding? The Economic Journal, 120(542), pp. F129–F156.CrossRefGoogle Scholar
Grossman, G. M. and Lai, E. L.-C., 2008. Parallel imports and price controls. RAND Journal of Economics, 39, pp. 378–402.CrossRefGoogle Scholar
Gupta, A., 2021. Impacts of performance pay for hospitals: The readmissions reduction program. American Economic Review, 111(4), pp. 1241–1283.CrossRefGoogle Scholar
Gutacker, N., Siciliani, L., and Cookson, R., 2016a. Waiting time prioritisation: Evidence from England. Social Science & Medicine, 159, pp. 140–151.CrossRefGoogle ScholarPubMed
Gutacker, N., Siciliani, L., Moscelli, G., and Gravelle, H., 2016b. Choice of hospital: Which type of quality matters? Journal of Health Economics, 50, pp. 230–246.CrossRefGoogle ScholarPubMed
Hafsteinsdottir, E. J. G. and Siciliani, L., 2010. DRG prospective payment systems: Refine or not refine? Health Economics, 19(10), pp. 1226–1239.CrossRefGoogle ScholarPubMed
Hall, J., Fiebig, D. G., and Van Gool, K., 2020. Private finance publicly subsidized: The case of Australian health insurance. In Private Health Insurance. Cambridge: Cambridge University Press, pp. 41–64.Google Scholar
Hedge, D., 2009. Political influence behind the veil of peer review: An analysis of public biomedical research funding in the United States. Journal of Law and Economics, 52(4), pp. 665–690.Google Scholar
Herr, A., 2008. Cost and technical efficiency of German hospitals: Does ownership matter? Health Economics, 17(9), pp. 1057–1071.CrossRefGoogle ScholarPubMed
Herr, A., Schmitz, H., and Augurzky, B., 2011. Profit efficiency and ownership of German hospitals. Health Economics, 20(6), pp. 660–674.CrossRefGoogle ScholarPubMed
Hollingsworth, B., 2008. The measurement of efficiency and productivity of health care delivery. Health Economics, 17(10), pp. 1107–1128.CrossRefGoogle ScholarPubMed
Holmstrom, B. and Milgrom, P., 1991. Multitask principal–agent analyses: Incentive contracts, asset ownership, and job design. The Journal of Law, Economics, and Organization, 7(special issue), pp. 24–52.CrossRefGoogle Scholar
Iizuka, T., 2012. Physician agency and adoption of generic pharmaceutical. American Economic Review, 102, pp. 2826–2858.CrossRefGoogle Scholar
Ito, Y., Hara, K., and Kobayashi, Y., 2020. The effect of inertia on brand-name versus generic drug choices. Journal of Economic Behavior & Organization, 172, pp. 364–379.CrossRefGoogle Scholar
Iversen, T., 1997. The effect of a private sector on the waiting time in a national health service. Journal of Health Economics, 16(4), pp. 381–396.CrossRefGoogle Scholar
Januleviciute, J., Askildsen, J. E., Kaarboe, O., Siciliani, L., and Sutton, M., 2016. How do hospitals respond to price changes? Evidence from Norway. Health Economics, 25(5), pp. 620–636.CrossRefGoogle Scholar
Jensen, P. H., Webster, E., and Witt, J., 2009. Hospital type and patient outcomes: An empirical examination using AMI readmission and mortality records. Health Economics, 18(12), pp. 1440–1460.CrossRefGoogle ScholarPubMed
Johar, M., Jones, G., Keane, M. P., Savage, E., and Stavrunova, O., 2013. Discrimination in a universal health system: Explaining socioeconomic waiting time gaps. Journal of Health Economics, 32(1), pp. 181–194.CrossRefGoogle Scholar
Kaarboe, O. and Siciliani, L., 2011. Multi‐tasking, quality and pay for performance. Health Economics, 20(2), pp. 225–238.CrossRefGoogle ScholarPubMed
Kaarboe, O. and Carlsen, F., 2014. Waiting times and socioeconomic status: Evidence from Norway. Health Economics, 23(1), pp. 93–107.CrossRefGoogle ScholarPubMed
Kaiser, U., Mendez, S. J., Rønde, T., and Ullrich, H., 2014. Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark. Journal of Health Economics, 36, pp. 174–187.CrossRefGoogle ScholarPubMed
Keng, S.-H. and Sheu, S.-J., 2013. The effect of national health insurance on mortality and the SES-health gradient: Evidence from the elderly in Taiwan. Health Economics, 22(1), pp. 52–72.CrossRefGoogle ScholarPubMed
Kessler, D. P. and McClellan, M. B., 2000. Is hospital competition socially wasteful? The Quarterly Journal of Economics, 115(2), pp. 577–615.CrossRefGoogle Scholar
Kessler, D. P. and Geppert, J. J., 2005. The effects of competition on variation in the quality and cost of medical care. Journal of Economics & Management Strategy, 14(3), pp. 575–589.Google Scholar
Kifmann, M., 2017. Competition policy for health care provision in Germany. Health Policy, 121(2), pp. 119–125.CrossRefGoogle ScholarPubMed
Kifmann, M. and Siciliani, L., 2017. Average‐cost pricing and dynamic selection incentives in the hospital sector. Health Economics, 26(12), pp. 1566–1582.CrossRefGoogle ScholarPubMed
Konetzka, R. T., Stuart, E. A., and Werner, R. M., 2018. The effect of integration of hospitals and post-acute care providers on Medicare payment and patient outcomes. Journal of Health Economics, 61, pp. 244–258.CrossRefGoogle ScholarPubMed
Kortelainen, M., Markkanen, J., Siikanen, M., and Toivanen, O., 2024. The effects of price regulation on pharmaceutical expenditure and availability. CEPR working paper DP18497.Google Scholar
Kremer, M. R., 1998. Patent buyouts: A mechanism for encouraging innovation. Quarterly Journal of Economics, 113, pp. 1137–1167.CrossRefGoogle Scholar
Kremer, M. and Glennerster, R., 2004. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton: Princeton University Press.Google Scholar
Kreutzberg, A., Eckhardt, H., Milstein, R., and Busse, R., 2023. International strategies, experiences, and payment models to incentivise day surgery. Health Policy, 140, p. 104968.CrossRefGoogle ScholarPubMed
Kristensen, S. R., Siciliani, L., and Sutton, M., 2016. Optimal price-setting in pay for performance schemes in health care. Journal of Economic Behavior & Organization, 123, pp. 57–77.CrossRefGoogle Scholar
Kroneman, M., Boerma, W., Van Den Berg, M., et al., 2016. The Netherlands: Health system review. Health Systems in Transition, 18(2), pp. 1–239.Google ScholarPubMed
Kruse, F. M., Stadhouders, N. W., Adang, E. M., Groenewoud, S., and Jeurissen, P. P., 2018. Do private hospitals outperform public hospitals regarding efficiency, accessibility, and quality of care in the European Union? A literature review. The International Journal of Health Planning and Management, 33(2), pp. e434–e453.CrossRefGoogle ScholarPubMed
Kuhn, M. and Siciliani, L., 2009. Performance indicators for quality with costly falsification. Journal of Economics & Management Strategy, 18(4), pp. 1137–1154.Google Scholar
Kuklinski, D., Vogel, J., and Geissler, A., 2021. The impact of quality on hospital choice. Which information affects patients’ behavior for colorectal resection or knee replacement? Health Care Management Science, 24, pp. 185–202.CrossRefGoogle ScholarPubMed
Kyle, M. K., 2007. Pharmaceutical price controls and entry strategies. Review of Economics & Statistics, 89, 88–99.CrossRefGoogle Scholar
Kyle, M. K., 2018. Are important innovations rewarded? Evidence from pharmaceutical markets. Review of Industrial Organization, 53, pp. 211–234.CrossRefGoogle Scholar
Kyle, M. K., 2022. Incentives for pharmaceutical innovation: What’s working, what’s lacking. International Journal of Industrial Organization, 84, p. 102850.CrossRefGoogle Scholar
Kyle, M. K. and McGahan, A. M., 2012. Investments in pharmaceuticals before and after TRIPS. Review of Economics & Statistics, 94, pp. 1157–1172.CrossRefGoogle Scholar
Laudicella, M., Siciliani, L., and Cookson, R., 2012. Waiting times and socioeconomic status: Evidence from England. Social Science & Medicine, 74(9), pp. 1331–1341.CrossRefGoogle ScholarPubMed
Laudicella, M., Donni, P. L., and Smith, P. C., 2013. Hospital readmission rates: Signal of failure or success? Journal of Health Economics, 32(5), pp. 909–921.CrossRefGoogle ScholarPubMed
Lee, Y.-C., Huang, Y. T., Tsai, Y. W., et al., 2010. The impact of universal National Health Insurance on population health: The experience of Taiwan. BMC Health Services Research, 10(1), pp. 1–8.CrossRefGoogle ScholarPubMed
Lien, H. M., Chou, S. Y., and Liu, J. T., 2008. Hospital ownership and performance: Evidence from stroke and cardiac treatment in Taiwan. Journal of Health Economics, 27(5), pp. 1208–1223.CrossRefGoogle ScholarPubMed
Limwattananon, S., Neelsen, S., O’Donnell, O., et al., 2015. Universal coverage with supply-side reform: The impact on medical expenditure risk and utilization in Thailand. Journal of Public Economics, 121, pp. 79–94.CrossRefGoogle Scholar
Lisi, D., Siciliani, L., and Straume, O. R., 2020. Hospital competition under pay‐for‐performance: Quality, mortality, and readmissions. Journal of Economics & Management Strategy, 29(2), pp. 289–314.Google Scholar
Luyten, E. and Tubeuf, S., 2024. Equity in healthcare financing: A review of evidence. Health Policy, 152, p. 105218.CrossRefGoogle Scholar
Ma, C. T. A., 1994. Health care payment systems: Cost and quality incentives. Journal of Economics & Management Strategy, 3(1), pp. 93–112.Google Scholar
Ma, Y., Nolan, A., and Smith, J. P., 2020. Free GP care and psychological health: Quasi-experimental evidence from Ireland. Journal of Health Economics, 72, p. 102351.CrossRefGoogle ScholarPubMed
Maini, L. and Pammolli, F., 2023. Reference pricing as a deterrent to entry: Evidence from the European Pharmaceutical Market. American Economic Journal: Microeconomics, 15, pp. 345–383.Google Scholar
Manning, W. G., Newhouse, J.P., Duan, N., Keeler, E.B., and Leibowitz, A., 1987. Health insurance and the demand for medical care: Evidence from a randomized experiment. American Economic Review, 77, pp. 251–277.Google ScholarPubMed
Marini, G., Miraldo, M., Jacobs, R., and Goddard, M., 2008. Giving greater financial independence to hospitals – does it make a difference? The case of English NHS trusts. Health Economics, 17(6), pp. 751–775.CrossRefGoogle ScholarPubMed
Martin, S. and Smith, P. C., 1999. Rationing by waiting lists: An empirical investigation. Journal of Public Economics, 71(1), pp. 141–164.CrossRefGoogle Scholar
Martin, S. and Smith, P. C., 2003. Using panel methods to model waiting times for National Health Service surgery. Journal of the Royal Statistical Society Series A: Statistics in Society, 166(3), pp. 369–387.CrossRefGoogle Scholar
Martin, S., Rice, N., Jacobs, R., and Smith, P., 2007. The market for elective surgery: Joint estimation of supply and demand. Journal of Health Economics, 26(2), pp. 263–285.CrossRefGoogle ScholarPubMed
McClellan, M., 1997. Hospital reimbursement incentives: An empirical analysis. Journal of Economics & Management Strategy, 6(1), pp. 91–128.Google Scholar
McGuire, T. G., 2011. Demand for health insurance. Handbook of Health Economics, 2, pp. 317–396.CrossRefGoogle Scholar
Mellor, J., Daly, M., and Smith, M., 2017. Does it pay to penalize hospitals for excess readmissions? Intended and unintended consequences of Medicare’s Hospital Readmissions Reductions Program. Health Economics, 26(8), pp. 1037–1051.CrossRefGoogle ScholarPubMed
Mendelson, A., Kondo, K., Damberg, C., et al., 2017. The effects of pay-for-performance programs on health, health care use, and processes of care: A systematic review. Annals of Internal Medicine, 166(5), pp. 341–353.CrossRefGoogle ScholarPubMed
Milcent, C., 2005. Hospital ownership, reimbursement systems and mortality rates. Health Economics, 14(11), pp. 1151–1168.CrossRefGoogle ScholarPubMed
Milstein, R. and Schreyoegg, J., 2016. Pay for performance in the inpatient sector: A review of 34 P4P programs in 14 OECD countries. Health Policy, 120(10), pp. 1125–1140.CrossRefGoogle ScholarPubMed
Mohanan, M., Donato, K., Miller, G., Truskinovsky, Y., and Vera-Hernández, M., 2021. Different strokes for different folks? Experimental evidence on the effectiveness of input and output incentive contracts for health care providers with varying skills. American Economic Journal: Applied Economics, 13(4), pp. 34–69.Google Scholar
Monstad, K., Engesæter, L. B., and Espehaug, B., 2014. Waiting time and socioeconomic status – An individual‐level analysis. Health Economics, 23(4), pp. 446–461.CrossRefGoogle ScholarPubMed
Morciano, M., Checkland, K., Billings, J. et al., 2020. New integrated care models in England associated with small reduction in hospital admissions in longer-term: A difference-in-differences analysis. Health Policy, 124(8), pp. 826–833.CrossRefGoogle ScholarPubMed
Moreno-Torres, I., Puig-Junoy, J., and Borrell, J.-R., 2009. Generic entry into the regulated Spanish pharmaceutical market. Review of Industrial Organization, 34, pp. 373–388.CrossRefGoogle Scholar
Moscelli, G., Siciliani, L., and Tonei, V., 2016a. Do waiting times affect health outcomes? Evidence from coronary bypass. Social Science & Medicine, 161, pp. 151–159.CrossRefGoogle ScholarPubMed
Moscelli, G., Siciliani, L., Gutacker, N., and Gravelle, H., 2016b. Location, quality and choice of hospital: Evidence from England 2002–2013. Regional Science and Urban Economics, 60, pp. 112–124.CrossRefGoogle ScholarPubMed
Moscelli, G., Gravelle, H., Siciliani, L., and Santos, R., 2018a. Heterogeneous effects of patient choice and hospital competition on mortality. Social Science & Medicine, 216, pp. 50–58.CrossRefGoogle ScholarPubMed
Moscelli, G., Gravelle, H., Siciliani, L., and Gutacker, N., 2018b. The effect of hospital ownership on quality of care: Evidence from England. Journal of Economic Behavior & Organization, 153, pp. 322–344.CrossRefGoogle Scholar
Moscelli, G., Siciliani, L., Gutacker, N., and Cookson, R., 2018c. Socioeconomic inequality of access to healthcare: Does choice explain the gradient? Journal of Health Economics, 57, pp. 290–314.CrossRefGoogle ScholarPubMed
Moscelli, G., Gravelle, H., and Siciliani, L., 2021. Hospital competition and quality for non‐emergency patients in the English NHS. The RAND Journal of Economics, 52(2), pp. 382–414.CrossRefGoogle Scholar
Moscone, F., Siciliani, L., Tosetti, E., and Vittadini, G., 2020. Do public and private hospitals differ in quality? Evidence from Italy. Regional Science and Urban Economics, 83, p. 103523.CrossRefGoogle Scholar
Nikolova, S., Harrison, M., and Sutton, M., 2016. The impact of waiting time on health gains from surgery: Evidence from a national patient‐reported outcome dataset. Health Economics, 25(8), pp. 955–968.CrossRefGoogle ScholarPubMed
Nyman, J. A., Koc, C., Dowd, B. E., McCreedy, E., and Trenz, H. M., 2018. Decomposition of moral hazard. Journal of Health Economics, 57, pp. 168–178.CrossRefGoogle ScholarPubMed
Nyman, J. A., 1999a. The value of health insurance: The access motive. Journal of Health Economics, 18, pp. 141–152.CrossRefGoogle ScholarPubMed
Nyman, J. A., 1999b. The economics of moral hazard revisited. Journal of Health Economics, 18, pp. 811–824.CrossRefGoogle ScholarPubMed
OECD, 2013. Waiting Time Policies in the Health Sector What Works? OECD Health Policy Studies.Google Scholar
OECD, 2020. Waiting Times for Health Services: Next in Line. OECD Health Policy Studies.Google Scholar
OECD, 2023. Health at a Glance 2023: OECD Indicators, Paris, https://doi.org/10.1787/7a7afb35-en.Google Scholar
Or, Z., Rococco, E., Touré, M., and Bonastre, J., 2022. Impact of competition versus centralisation of hospital care on process quality: A multilevel analysis of breast cancer surgery in France. International Journal of Health Policy and Management, 11(4), pp. 459–469.Google ScholarPubMed
Panhans, M., 2019. Adverse selection in ACA exchange markets: Evidence from Colorado. American Economic Journal: Applied Economics, 11(2), pp. 1–36.Google Scholar
Papanicolas, I. and McGuire, A., 2015. Do financial incentives trump clinical guidance? Hip replacement in England and Scotland. Journal of Health Economics, 44, pp. 25–36.CrossRefGoogle Scholar
Paris, V. and Belloni, A., 2013. Value in pharmaceutical pricing. OECD Health Working Paper no. 63.Google Scholar
Pecorino, P., 2002. Should the US allow prescription drug reimports from Canada? Journal of Health Economics, 21, pp. 699–708.CrossRefGoogle ScholarPubMed
Pérotin, V., Zamora, B., Reeves, R., Bartlett, W., and Allen, P., 2013. Does hospital ownership affect patient experience? An investigation into public–private sector differences in England. Journal of Health Economics, 32(3), pp. 633–646.CrossRefGoogle ScholarPubMed
Pinchbeck, E. W., 2019. Convenient primary care and emergency hospital utilisation. Journal of Health Economics, 68, p. 102242.CrossRefGoogle ScholarPubMed
Propper, C., Burgess, S., and Green, K., 2004. Does competition between hospitals improve the quality of care? Hospital death rates and the NHS internal market. Journal of Public Economics, 88(7–8), pp. 1247–1272.CrossRefGoogle Scholar
Propper, C., Sutton, M., Whitnall, C., and Windmeijer, F., 2008a. Did ‘targets and terror’ reduce waiting times in England for hospital care? The BE Journal of Economic Analysis & Policy, 8(2), pp. 1–25.Google Scholar
Propper, C., Burgess, S., and Gossage, D., 2008b. Competition and quality: Evidence from the NHS internal market 1991–9. The Economic Journal, 118(525), pp. 138–170.CrossRefGoogle Scholar
Propper, C., Sutton, M., Whitnall, C., and Windmeijer, F., 2010. Incentives and targets in hospital care: Evidence from a natural experiment. Journal of Public Economics, 94(3–4), pp. 318–335.CrossRefGoogle Scholar
Rawls, J., 1971. A Theory of Justice, Cambridge, MA: Belknap Press of Harvard University Press. Retrieved from https://philpapers.org/rec/RAWATO-4.CrossRefGoogle Scholar
Regan, T. L., 2008. Generic entry, price competition, and market segmentation in the prescription drug market. International Journal of Industrial Organization, 26, pp. 930–948.CrossRefGoogle Scholar
Reisinger, M., Saurí, L., and Zenger, H., 2019. Parallel imports, price controls, and innovation. Journal of Health Economics, 66, pp. 163–179.CrossRefGoogle ScholarPubMed
Riganti, A., Siciliani, L., and Fiorio, C. V., 2017. The effect of waiting times on demand and supply for elective surgery: Evidence from Italy. Health Economics, 26, pp. 92–105.CrossRefGoogle ScholarPubMed
Roos, A. F., O’Donnell, O., Schut, F. T. et al., 2020. Does price deregulation in a competitive hospital market damage quality? Journal of Health Economics, 72, p. 102328.CrossRefGoogle Scholar
Rothschild, M. and Stiglitz, J., 1976. Imperfect information. The Quarterly Journal of Economics, 90(4), pp. 629–649.CrossRefGoogle Scholar
Roy, S. and Saggi, K., 2012. Equilibrium parallel import policies and international market structure. Journal of International Economics, 87, pp. 262–276.CrossRefGoogle Scholar
Rudholm, N., 2001. Entry and the number of firms in the Swedish pharmaceutical market. Review of Industrial Organization, 19, pp. 351–364.CrossRefGoogle Scholar
Sampat, B. N. and Lichtenberg, F. R., 2011. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs, 30(2), pp. 332–339.CrossRefGoogle ScholarPubMed
Santos, R., Gravelle, H., and Propper, C., 2017. Does quality affect patients’ choice of doctor? Evidence from England. The Economic Journal, 127(600), pp. 445–494.CrossRefGoogle ScholarPubMed
Santos, A. S., Guerra-Junior, A. A., de Sousa Noronha, K. V. M., Andrade, M. V., and Ruas, C. M., 2019. The price of substitute technologies. Value in Health Regional Issues, 20, pp. 154–158.CrossRefGoogle Scholar
Sarpatwari, A., Beall, R. F., Abdurrob, A., He, M., and Kesselheim, A. S., 2018. Evaluating the impact of the Orphan Drug Act’s seven-year market exclusivity period. Health Affairs, 37(5), pp. 732–737.CrossRefGoogle ScholarPubMed
Schut, F. T. and Varkevisser, M., 2017. Competition policy for health care provision in the Netherlands. Health Policy, 121(2), pp. 126–133.CrossRefGoogle ScholarPubMed
Sharma, A., Siciliani, L., and Harris, A., 2013. Waiting times and socioeconomic status: Does sample selection matter? Economic Modelling, 33, pp. 659–667.CrossRefGoogle Scholar
Shen, Y. C., 2002. The effect of hospital ownership choice on patient outcomes after treatment for acute myocardial infarction. Journal of Health Economics, 21(5), pp. 901–922.CrossRefGoogle ScholarPubMed
Shin, E., 2019. Hospital responses to price shocks under the prospective payment system. Health Economics, 28(2), pp. 245–260.CrossRefGoogle Scholar
Siciliani, L., 2009. Paying for performance and motivation crowding out. Economics Letters, 103(2), pp. 68–71.CrossRefGoogle Scholar
Siciliani, L., 2014. Rationing of demand. In Culyer, A. J., ed., Encyclopedia of Health Economics. Amsterdam: Newnes.Google Scholar
Siciliani, L., Chalkley, M., and Gravelle, H., 2022. Does provider competition improve health care quality and efficiency? Expectations and evidence from Europe, Policy Brief n.48, European Observatory of Health Systems and Policies, pp. 1–35.Google Scholar
Simon, K., Soni, A., and Cawley, J., 2017. The impact of health insurance on preventive care and health behaviors: Evidence from the first two years of the ACA Medicaid expansions. Journal of Policy Analysis and Management, 36(2), pp. 390–417.CrossRefGoogle ScholarPubMed
Siu, A. L., Sonnenberg, F. A., Manning, W. G., et al., 1986. Inappropriate use of hospitals in a randomized trial of health insurance plans. New England Journal of Medicine, 315(20), pp. 1259–1266CrossRefGoogle Scholar
Sloan, F. A., 2000. Not-for-profit ownership and hospital behavior. Handbook of Health Economics, 1, pp. 1141–1174.CrossRefGoogle Scholar
Sparrow, R., Suryahadi, A., and Widyanti, W., 2013. Social health insurance for the poor: Targeting and impact of Indonesia’s Askeskin programme. Social Science & Medicine, 96, pp. 264–271.CrossRefGoogle ScholarPubMed
Stavrunova, O. and Yerokhin, O., 2011. An equilibrium model of waiting times for elective surgery in NSW public hospitals. Economic Record, 87(278), pp. 384–398.CrossRefGoogle Scholar
Stevens, A. J., Jensen, J. J., Wyller, K., et al., 2011. The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine, 364(6), pp. 535–541.CrossRefGoogle ScholarPubMed
Stolper, K. C. F., Boonen, L. H., Schut, F. T., and Varkevisser, M., 2022. Do health insurers use target marketing as a tool for risk selection? Evidence from the Netherlands. Health Policy, 126(2), pp. 122–128.CrossRefGoogle ScholarPubMed
Straume, O. R., 2023. Therapeutic reference pricing and drug innovation incentives. Economics Letters, 222, p. 110945.CrossRefGoogle Scholar
Sutton, M., Elder, R., Guthrie, B., and Watt, G., 2010. Record rewards: The effects of targeted quality incentives on the recording of risk factors by primary care providers. Health Economics, 19(1), pp. 1–13.CrossRefGoogle ScholarPubMed
Sutton, M., Nikolova, S., Boaden, R. et al., 2012. Reduced mortality with hospital pay for performance in England. New England Journal of Medicine, 367(19), pp. 1821–1828.CrossRefGoogle ScholarPubMed
Toole, A. A., 2012. The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry. Research Policy, 41, pp. 1–12.CrossRefGoogle Scholar
Turner, B. and Smith, S., 2020. Uncovering the complex role of private health insurance in Ireland. In Thomson, S., Sagan, A., and Mossialos, E., eds., Private Health Insurance. Cambridge: Cambridge University Press, pp. 221–263.Google Scholar
van de Ven, W. P. M. M. and van Vliet, R. C. J. A., 1992. How can we prevent cream skimming in a competitive health insurance market? In Zweifel, P. and Frech, H. E. III, eds., Health Economics Worldwide. Dordrecht: Kluwer, pp. 23–46.CrossRefGoogle Scholar
Varkevisser, M., van der Geest, S. A., and Schut, F. T., 2012. Do patients choose hospitals with high quality ratings? Empirical evidence from the market for angioplasty in the Netherlands. Journal of Health Economics, 31(2), pp. 371–378.CrossRefGoogle ScholarPubMed
Vernon, J. A., 2005. Examining the link between price regulation and pharmaceutical R&D investment. Health Economics, 14, pp. 1–16.CrossRefGoogle ScholarPubMed
Wagstaff, A. and Van Doorslaer, E., 1992. Equity in the finance of health care: Some international comparisons. Journal of Health Economics, 11(4), pp. 361–387.CrossRefGoogle ScholarPubMed
Wagstaff, A., Van Doorslaer, E., Van der Burg, H., et al., 1999. Equity in the finance of health care: Some further international comparisons. Journal of Health Economics, 18(3), pp. 263–290.CrossRefGoogle ScholarPubMed
Wagstaff, A. and Van Doorslaer, E., 2000. Equity in health care finance and delivery. Handbook of Health Economics, 1, pp. 1803–1862.CrossRefGoogle Scholar
Werner, R. M., Kolstad, J. T., Stuart, E. A., and Polsky, D., 2011. The effect of pay-for-performance in hospitals: Lessons for quality improvement. Health Affairs, 30(4), pp. 690–698.CrossRefGoogle ScholarPubMed
Wiggins, S. N. and Maness, R., 2004. Price competition in pharmaceuticals: The case of anti-infectives. Economic Inquiry, 42, pp. 247–263.CrossRefGoogle Scholar
Yang, O., Yong, J., and Zhang, Y., 2024. Effects of private health insurance on waiting time in public hospitals. Health Economics, 33(6), pp. 1192–1210.CrossRefGoogle ScholarPubMed
Zeckhauser, R. J., 1970. Medical insurance: A case study of the tradeoff between risk spreading and appropriate incentives. Journal of Economic Theory, 2, pp. 10–26.CrossRefGoogle Scholar
Zweifel, P., Breyer, F., and Kifmann, M., 2009. Health Economics, 2nd ed., Berlin: Springer Science and Business Media.CrossRefGoogle Scholar